The invention concerns compounds of the formula
wherein B is a moiety having the formula:
the dotted line represents a bond which is present when B is formula Id or If and absent when B isformula le, R is hydrogen, mono- or dihalo, amino, nitro, cyano, hydroxy, trifluoromethyl, mercapto, lower alkyl, lower alkoxy, alkanoyl, lowercycloalkyl, carboxy, alkoxycarbonyl, mono- or di-lower alkyl substituted amino, alkamoylamino, lower alkyl thio, loweralkyl-sulfonyl, sulfamoyl, lower alkyl substituted sulfamoyl, phenyl or phenyl substituted with halo, lower alkyl, lower alkoxy,trifluoromethyl, hydroxy, amino, cyano or nitro; X is SO 2 , SO, S or C=O and A is an amine of formula:


wherein n is 1 to 4; R' is hydrogen or R 2 CH2 wherein R 2 is mono- or diloweralkylamino, mono- or di-N-lower- alkylamino lower alkyl, (2-furyl)methylamino, benzylamino, lower cycloalkylamino of 5 to 7 carbon atoms, 1-pyrrolidinyl, 1-piperidinyl, 1-hexahydroazepinyl, 1-octahydroazocinyl, 3-thiazolidinyl,4-morpholinyl or4-thiomorpholinyl; R 3 is hydrogen or (1-piperidinyl)-methyl with the proviso that when R 3 is (1-piperidinyl)-methyl, then R' is hydrogen; and the pharmacologically acceptable salts thereof which inhibit gastic acid secretion. Processes for preparing the compounds and pharmaceutical compositions containing them are also disclosed.